Author details

Full Name

Bryan W Day

Affiliation

ORCID

Career Start Year

2005

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36976462	Clinical Trials in the Brain Tumour Population: Challenges and Strategies for the Future.	Curr Oncol Rep	2023
37031458	A pilot study: Metabolic profiling of plasma and saliva samples from newly diagnosed glioblastoma patients.		2023
37145169	ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma.	Cancer Res	2023
37333134	Preventing recurrence in Sonic Hedgehog Subgroup Medulloblastoma using the OLIG2 inhibitor CT-179.	Res Sq	2023
37143361	Development and Validation of a Targeted Treatment for Brain Tumors Using a Multi-Drug Loaded, Relapse-Resistant Polymeric Theranostic.		2023
36484477	A Multifunctional Porous Silicon Nanocarrier for Glioblastoma Treatment.		2023
37254878	Proteome profiling of salivary small extracellular vesicles in glioblastoma patients.		2023
37195023	ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma.	Cancer Res	2023
37001527	Generation and multi-dimensional profiling of a childhood cancer cell line atlas defines new therapeutic opportunities.	Cancer Cell	2023
35053502	STAT3 Enhances Sensitivity of Glioblastoma to Drug-Induced Autophagy-Dependent Cell Death.	Cancers	2022
35406779	Transcriptomic Profiling of DNA Damage Response in Patient-Derived Glioblastoma Cells before and after Radiation and Temozolomide Treatment.	Cells	2022
36547195	Determining the Research Priorities for Adult Primary Brain Tumours in Australia and New Zealand: A Delphi Study with Consumers, Health Professionals, and Researchers.		2022
34232320	A novel patient stratification strategy to enhance the therapeutic efficacy of dasatinib in glioblastoma.	Neuro Oncol	2022
35324780	Engineering Novel Lentiviral Vectors for Labelling Tumour Cells and Oncogenic Proteins.	Bioengineering	2022
33863878	Global phosphoproteomics reveals DYRK1A regulates CDK1 activity in glioblastoma cells.	Cell Death Discov	2021
37185327	LUMOS - Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS at relapse: Protocol for a pilot study.	BMJ Open	2021
33637089	Effectiveness of porous silicon nanoparticle treatment at inhibiting the migration of a heterogeneous glioma cell population.	Journal of Nanobiotechnology	2021
33571503	MerTK activity is not necessary for the proliferation of glioblastoma stem cells.	Biochemical Pharmacology	2021
34150645	Isolation of Circulating Tumour Cells in Patients With Glioblastoma Using Spiral Microfluidic Technology - A Pilot Study.	Frontiers in Oncology	2021
33924599	DYRK1A Negatively Regulates CDK5-SOX2 Pathway and Self-Renewal of Glioblastoma Stem Cells.	International Journal of Molecular Sciences	2021
33919246	A Drug Screening Pipeline Using 2D and 3D Patient-Derived In Vitro Models for Pre-Clinical Analysis of Therapy Response in Glioblastoma.	International Journal of Molecular Sciences	2021
31504812	Simultaneous targeting of DNA replication and homologous recombination in glioblastoma with a polyether ionophore.	Neuro Oncol	2020
32079743	Constitutive CHK1 Expression Drives a pSTAT3-CIP2A Circuit that Promotes Glioblastoma Cell Survival and Growth.	Molecular Cancer Research	2020
31965010	Publisher Correction: A reference collection of patient-derived cell line and xenograft models of proneural, classical and mesenchymal glioblastoma.	Sci Rep	2020
32257282	Driving innovation through collaboration: development of clinical annotation datasets for brain cancer biobanking.	Neurooncol Pract	2020
32354330	Direct evidence for transport of RNA from the mouse brain to the germline and offspring.	BMC Biology	2020
32168910	MK2 Inhibition Induces p53-Dependent Senescence in Glioblastoma Cells.	Cancers (Basel)	2020
32165640	Digenic inheritance of mutations in EPHA2 and SLC26A4 in Pendred syndrome.	Nature Communications	2020
31666668	Circulating biomarkers in patients with glioblastoma.	British Journal of Cancer	2020
31760595	Transcription factors NFIA and NFIB induce cellular differentiation in high-grade astrocytoma.	Journal of Neuro-Oncology	2020
32483457	Comparative study of preclinical mouse models of high-grade glioma for nanomedicine research: the importance of reproducing blood-brain barrier heterogeneity.	Theranostics	2020
31973233	Q-Cell Glioblastoma Resource: Proteomics Analysis Reveals Unique Cell-States are Maintained in 3D Culture.	Cells	2020
32642689	MR-guided focused ultrasound increases antibody delivery to nonenhancing high-grade glioma.	Neurooncol Adv	2020
33082953	Endothelial, pericyte and tumor cell expression in glioblastoma identifies fibroblast activation protein (FAP) as an excellent target for immunotherapy.	Clinical and Translational Immunology	2020
33014146	Clinicopathologic significance of nuclear HER4 and phospho-YAP(S<sup>127</sup>) in human breast cancers and matching brain metastases.	Ther Adv Med Oncol	2020
31362788	Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.	Acta neuropathologica communications	2019
32259073	Lower Tubulin Expression in Glioblastoma Stem Cells Attenuates Efficacy of Microtubule-Targeting Agents.	ACS Pharmacol Transl Sci	2019
30511336	Granule neuron precursor cell proliferation is regulated by NFIX and intersectin 1 during postnatal cerebellar development.	Brain Struct Funct	2019
30353492	Extracellular Vesicles Released by Glioblastoma Cells Stimulate Normal Astrocytes to Acquire a Tumor-Supportive Phenotype Via p53 and MYC Signaling Pathways.	Molecular Neurobiology	2019
30250299	Cytoplasmic dynein regulates the subcellular localization of sphingosine kinase 2 to elicit tumor-suppressive functions in glioblastoma.	Oncogene	2019
30535593	Tropomyosin Tpm 2.1 loss induces glioblastoma spreading in soft brain-like environments.	Journal of Neuro-Oncology	2019
31463571	The dystroglycan receptor maintains glioma stem cells in the vascular niche.	Acta Neuropathol	2019
30736342	Intratumoural Heterogeneity Underlies Distinct Therapy Responses and Treatment Resistance in Glioblastoma.	Cancers (Basel)	2019
30894629	A reference collection of patient-derived cell line and xenograft models of proneural, classical and mesenchymal glioblastoma.	Sci Rep	2019
29564746	ATM inhibition prevents interleukin-6 from contributing to the proliferation of glioblastoma cells after ionizing radiation.	Journal of Neuro-Oncology	2018
29944980	Changes in cell morphology guide identification of tubulin as the off-target for protein kinase inhibitors.	Pharmacol Res	2018
30562956	EphA3 Pay-Loaded Antibody Therapeutics for the Treatment of Glioblastoma.	Cancers	2018
28178667	Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells.	Oncotarget	2017
28777932	Long Noncoding RNAs CUPID1 and CUPID2 Mediate Breast Cancer Risk at 11q13 by Modulating the Response to DNA Damage.	Am J Hum Genet	2017
28690875	Combination of palbociclib and radiotherapy for glioblastoma.	Cell Death Discov	2017